JP2020094029A - Oral composition - Google Patents

Abstract

To provide an oral composition having excellent adhesion to gums or oral mucosa, and a method for enhancing the adhesion of an oral composition to gums.SOLUTION: An oral composition is prepared that contains (A) fatty acid dextrin, (B) a polymer compound and/or abrasive, and (C) water.SELECTED DRAWING: None

Description

The present invention relates to an oral composition.

Oral compositions such as dentifrices and gels containing active ingredients such as anti-inflammatory agents and bactericides for use in the prevention and treatment of periodontal diseases such as periodontitis (alveolar pyorrhea) and gum inflammation Are known. Patent Document 1 discloses a water-soluble pyridinium compound, a quaternary ammonium compound or a biguanide fungicide, a cationized hydroxyethyl cellulose having a specific molecular weight and a cationization degree, a specific surfactant, and a specific amount of a non-silica type. A toothpaste composition containing an abrasive is disclosed.

JP, 6-239725, A

An object of the present invention is to provide an oral composition having excellent adhesion to gums or oral mucosa in the above-mentioned situation.

As a result of intensive studies, the present inventors have high adhesion to the gum surface by containing (A) fatty acid dextrin, (B) polymer compound and/or abrasive, and (C) water. The inventors have found that a composition for oral cavity can be prepared, and have completed the present invention.

That is, the present invention provides the following oral compositions.
Item 1.
An oral composition containing (A) a fatty acid dextrin, (B) a polymer compound and/or an abrasive, and (C) water.
Item 2.
Item 2. The oral composition according to Item 1, wherein the polymer compound and/or the polishing agent (B) is a linear polymer compound.
Item 3.
Item (1) or (2), in which the polymer compound (B) and/or the abrasive is at least one selected from the group consisting of carboxyvinyl polymer, alginic acid or a salt thereof, pullulan, and a cellulosic polymer. Oral composition.
Item 4.
Item 4. The oral composition according to any one of Items 1 to 3, wherein the total content of the component (B) is 0.01 to 500 parts by mass relative to the total content of the component (A) of 1 part by mass.
Item 5.
(C) The oral cavity composition according to any one of Items 1 to 4, which contains 30% by mass or more of water.
Item 6.
(A) The composition for oral cavity according to any one of Items 1 to 5, wherein the fatty acid dextrin is dextrin palmitate.
Item 7.
Item 7. The oral composition according to any one of Items 1 to 6, further containing at least one selected from the group consisting of a bactericide, a tissue repair agent, an anti-inflammatory agent, and a blood circulation promoter.
Item 8.
Further, the oral composition according to any one of Items 1 to 7, which contains a higher alcohol.
Item 9.
Furthermore, the composition for oral cavity of any one of claim|item 1-8 containing a surfactant.
Item 10.
Further, the oral composition according to any one of Items 1 to 9, which contains a hydrocarbon.
Item 11.
Item 11. The oral composition according to any one of Items 1 to 10, which is a dentifrice, a coating agent, or a mouthwash.

Furthermore, the present invention provides the following methods.
Item 12.
A method for enhancing the adhesion of an oral composition to the gums, which comprises the step of containing (A) a fatty acid dextrin, (B) a polymer compound and/or an abrasive, and (C) water.

The oral composition of the present invention has enhanced adhesion to oral tissues such as gums and oral mucosa. As a result, the water-soluble and oil-soluble medicinal components and the like can be brought into close contact with the oral tissue together with the base, and the medicinal action of the drug in the oral cavity can be enhanced.

[Composition for oral cavity]
The oral composition of the present invention is an oral composition containing (A) a fatty acid dextrin, (B) a polymer compound and/or an abrasive, and (C) water.

[(A) Fatty acid dextrin]
The fatty acid dextrin refers to an ester compound of dextrin and fatty acid.

The fatty acid constituting the fatty acid dextrin preferably has 6 to 24 carbon atoms, and examples thereof include palmitic acid, stearic acid, arachidic acid, octanoic acid, capric acid, lauric acid, myristic acid, and behenic acid. Among them, palmitic acid is preferable as the fatty acid that constitutes the fatty acid dextrin, from the viewpoint that the effect of the present invention is more remarkably exhibited.

The fatty acid dextrin contained in the oral composition of the present invention may be composed of one or more fatty acids.

The fatty acid dextrin is not particularly limited as long as it is generally used in the fields of pharmaceuticals, quasi drugs or cosmetics, and, for example, commercially available products can be used, and the trade name is “Leopearl KL (display name: dextrin palmitate). "(Chiba Flour Milling Co., Ltd.), "Leopearl KL2 (Display name: dextrin palmitate)" (Chiba Flour Milling Co., Ltd.), product name "Leopearl TL (display name: Dextrin palmitate dextrin)" (Chiba Flourishing Co., Ltd.) , Product name "Leopearl TL2 (display name: dextrin palmitate)" (manufactured by Chiba Flour Milling Co., Ltd.), product name "Leopearl TT (display name: (palmitic acid/octanoic acid) dextrin)" (manufactured by Chiba Milling Co., Ltd.), The trade name is "Leopard TT2 (display name: (palmitic acid/octanoic acid) dextrin)" (manufactured by Chiba Flour Milling Co., Ltd.) and the like.

The content of the component (A) is not particularly limited, but from the viewpoint of enhancing the adhesion to oral tissues, it is preferably 0.01% by mass or more, and more preferably 0.05% by mass with respect to the total amount of the oral composition. It is at least mass%, more preferably at least 0.1 mass%, particularly preferably at least 0.25 mass%.

The content of the component (A) is preferably 2% by mass or less, more preferably 1% by mass or less, and particularly preferably 0.75% by mass, based on the total amount of the oral composition, from the viewpoint of improving the feeling of use. % Or less.

The content of the component (A) is preferably 0.05 to 2% by mass, more preferably 0.1 to 1% by mass, and still more preferably 0.25 to 0.75, based on the total amount of the oral composition. It is% by mass.

[(B) Polymer Compound or Abrasive]
The polymer compound contained in the oral composition of the present invention may be a naturally derived substance or a substance obtained by chemical synthesis.

Examples of the polymer compound include carboxyvinyl polymer, sodium polyacrylate, polyvinyl alcohol, polyvinylpyrrolidone, alkyl methacrylate methacrylate copolymer, polyethylene glycol, macrogol, (hydroxyethyl acrylate/acryloyldimethyltaurine Na) copolymer. , (Acryloyldimethyltaurine ammonium/vinylpyrrolidone) copolymer, polypeptide (gelatin etc.), linear polysaccharide (alginic acid or its salt, pullulan, cellulosic polymer, pectin, carrageenan, gellan gum, agar, propylene glycol alginate, chondroitin Linear polymer compounds such as sodium sulfate, hyaluronic acid, sodium hyaluronate); branched polymer compounds such as guar gum, locust bean gum, xanthan gum, gum arabic, karaya gum, thickening anhydrous silicic acid and bentonite. Be done.

The abrasive contained in the composition for oral cavity of the present invention is not limited, for example, calcium hydrogen phosphate (dicalcium phosphate) dihydrate or anhydrate, calcium pyrophosphate, tricalcium phosphate, hydroxyapatite, Calcium phosphate-based abrasives such as quaternary calcium phosphate; silica-based abrasives such as silicic acid anhydride, crystalline silica, amorphous silica, silica gel, precipitated silica, aluminosilicate, and zirconosilicate; zeolite; calcium carbonate-based abrasive; Insoluble potassium metaphosphate; aluminum oxide; aluminum hydroxide; alumina; magnesium carbonate; magnesium triphosphate; zinc oxide; synthetic resin abrasives and the like can be used. Among them, calcium phosphate-based abrasives or silica-based abrasives are more preferred, calcium phosphate-based abrasives are still more preferred, and calcium hydrogen phosphate dihydrate or anhydrate is particularly preferred.

The component (B) is not particularly limited as long as it is generally used in the fields of medicines, quasi drugs or cosmetics, and for example, commercially available products can be used.

These (B) components may be used alone or in any combination of two or more. Although not limited, the component (B) is preferably a polymer compound, more preferably a linear polymer, from the viewpoint of significantly exhibiting the effect of the present invention and the viewpoint of reducing friction with the oral tissue, and carboxy. A component selected from the group consisting of vinyl polymer, alginic acid or a salt thereof, pullulan and a cellulosic polymer is more preferable. Further, the component (B) can be a combination of two or more kinds. When two or more kinds of the component (B) are combined, there is no limitation, and it is appropriately set according to the type and content of other compounding ingredients, the form of the formulation, the method of use, etc., but a carboxyvinyl polymer, alginic acid or a salt thereof, It is preferable to combine two or more selected from the group consisting of pullulan and a cellulosic polymer.

Carboxyvinyl polymer is a vinyl polymer mainly composed of acrylic acid having a carboxyl group, methacrylic acid, etc., there is no particular restriction on the monomer composition or molecular weight, and various commercially available carboxyvinyl polymers are not particularly limited. Can be used. Examples of these commercially available products include Carbopol 940, Carbopol 941, Carbopol 980, and Carbopol 981 sold by Lubrizol Advanced Materials. 981), Carbopol Ultrez10 (Carbopol Ultrez10), Carbopol ETD2050 (Carbopol ETD2050) and Hibiswako 103, Hibiswako 104, Hibiswako 105, Hibiswako 105 sold by Wako Pure Chemicals Co., and Shintalen sold by 3V Sigma. K, Synthalene L, and Apec HV-501 (AQUPEC HV-501), Apepek HV-504 (AQUPEC HV-504), Apepek HV-505 (AQUPEC HV-505), Apepek HV sold by Sumitomo Seika. -501E (AQUPEC HV-501E), Akpek HV-504E (AQUPEC HV-504E), Akpek HV-505E (AQUPEC HV-505E), Akpek HV-501ER (AQUPEC HV-501ER), Akpek HV-505ED (AQUPEC HV-) 505ED) and the like.

Alginic acid is a linear polysaccharide composed of two types of uronic acids, namely D-mannuronic acid (M) and L-guluronic acid (G). A commercial item can also be used for alginic acid. Examples of the salt of alginic acid in the present invention include, but are not limited to, sodium salt, potassium salt and the like. Preferred is sodium alginate. You may use alginic acid or its salt 1 type or in combination of 2 or more types. From the viewpoint of suitably adjusting the physical properties of the oral composition of the present invention, alginic acid or a salt thereof is more preferably used in combination with a calcium salt.

Pullulan is a water-soluble polysaccharide having a structure in which maltotriose in which three glucose molecules are each linked by α-1,4 are regularly linked by α-1,6-bonds. As a commercially available product, for example, one sold as a food additive by Hayashibara Co., Ltd. can be used.

The cellulose-based polymer compound is a cellulose-based polymer compound obtained by replacing the hydroxyl group of cellulose with another functional group. Examples of the functional group that replaces the hydroxyl group of cellulose include a methoxy group, an ethoxy group, a hydroxymethoxy group, a hydroxyethoxy group, a hydroxypropoxy group, a carboxymethoxy group, and a carboxyethoxy group. Specific examples of the cellulose-based polymer compound include methyl cellulose, ethyl cellulose, hydroxyethyl methyl cellulose, hydroxyethyl cellulose (HEC), hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), carboxymethyl cellulose (CMC) and salts thereof. (For example, carmellose sodium, carmellose calcium, carmellose ammonium), stearoxyhydroxypropyl methylcellulose, crystalline cellulose, O-[2-hydroxy-3-(trimethylammonio)propyl]hydroxyethyl cellulose chloride and the like. These cellulose-based polymers may be used alone or in combination of two or more. Moreover, as these cellulose-based polymer compounds, commercially available products may be used, and one kind or two or more kinds of these compounds may be used in combination.

The total content of the component (B) is not particularly limited and may be appropriately set depending on the types and contents of other compounding ingredients, the form of the formulation, the method of use, etc., but from the viewpoint of remarkably exerting the effect of the present invention. , Preferably 0.01% by mass or more, more preferably 0.05% by mass or more, further preferably 0.1% by mass or more, even more preferably 0.25% by weight or more, based on the total amount of the composition for oral cavity. , Particularly preferably 0.5% by mass or more.

The total content of the component (B) is preferably 50% by mass or less, more preferably 30% by mass or less, and further preferably 20% with respect to the total amount of the oral composition, from the viewpoint of remarkably exerting the effect of the present invention. It is not more than 15% by mass, particularly preferably not more than 15% by mass.

The total content of the component (B) is preferably 0.01 to 50% by mass, more preferably 0.05 to 30% by mass, and still more preferably 0.1 to 20% by mass based on the total amount of the oral composition. %, even more preferably 0.25 to 20% by weight, and particularly preferably 0.5 to 15% by weight.

When the component (B) is a polymer compound, the total content of the polymer compound is not particularly limited and may be appropriately set depending on the types and contents of other compounding ingredients, the form of the formulation, the method of use, etc. From the viewpoint of remarkably exerting the effect of the present invention, preferably 0.05 mass% or more, more preferably 0.1 mass% or more, still more preferably 0.5 mass% or more with respect to the total amount of the oral composition. , Particularly preferably 1% by mass or more.

When the component (B) is a polymer compound, the total content of the polymer compounds is preferably 7.5% by mass or less with respect to the total amount of the composition for oral cavity, from the viewpoint of remarkably exerting the effect of the present invention. , More preferably 5% by mass or less, further preferably 3% by mass or less, particularly preferably 2% by mass or less, and most preferably 1.5% by mass or less.

When the component (B) is a polymer compound, the total content of the polymer compounds is preferably 0.05 to 7.5% by mass, more preferably 0.1 to 7.5% by mass relative to the total amount of the oral composition. It is 5% by mass, more preferably 0.5 to 3% by mass, and particularly preferably 1 to 2% by mass.

Although not limited, in a preferred embodiment, for example, when a carboxyvinyl polymer is contained as the component (B), the content of the carboxyvinyl polymer alone is preferably 0.05 with respect to the total amount of the oral composition. ˜7.5% by mass, more preferably 0.1 to 5% by mass, even more preferably 0.5 to 2% by mass, particularly preferably 1 to 1.5% by mass.

Although not limited, in a preferred embodiment, for example, when alginic acid or a salt thereof is contained as the component (B), the content of alginic acid or a salt alone is preferably 0 relative to the total amount of the oral composition. 0.01 to 10% by mass, more preferably 0.05 to 5% by mass, still more preferably 0.1 to 2% by mass, and particularly preferably 0.3 to 1% by mass.

When the component (B) is an abrasive, the total content of the component (B) is not particularly limited, and is appropriately set according to the types and contents of other compounding components, the formulation form, the method of use, and the like. From the viewpoint of more remarkably exerting the effect of the present invention, it is preferably 0.5% by mass or more, more preferably 1% by mass or more, and further preferably 5% by mass or more based on the total amount of the oral composition.

When the component (B) is an abrasive, the total content of the component (B) is preferably 50% by mass or less based on the total amount of the composition for oral cavity, from the viewpoint of more conspicuously exhibiting the effect of the present invention. It is more preferably 20% by mass or less, still more preferably 15% by mass or less.

When the component (B) is an abrasive, the total content of the abrasive is preferably 0.5 to 50% by mass, more preferably 1 to 20% by mass, and still more preferably the total amount of the oral composition. Is 5 to 15% by mass.

[Ratio of each component]
The total content ((B)/(A)) of the component (B) per 1 part by mass of the total content of the component (A) in the oral composition of the present invention is not particularly limited, but the effect of the present invention is remarkable. From the viewpoint of achieving the above, the amount is preferably 0.01 to 500 parts by mass, more preferably 0.05 to 200 parts by mass, further preferably 0.1 to 100 parts by mass, and particularly preferably 0.5 to 50 parts by mass.

When the component (B) of the present invention is a polymer compound, the total content of the component (B) per part by mass of the component (A) in the oral composition of the present invention ((B)/(A )) is not particularly limited, but is preferably 0.1 to 50 parts by mass, more preferably 0.5 to 20 parts by mass, still more preferably 1 to 10 parts by mass, from the viewpoint of significantly exhibiting the effect of the present invention. It is particularly preferably 1.3 to 6 parts by mass.

When the component (B) of the present invention is an abrasive, the total content of the component (B) with respect to 1 part by mass of the total content of the component (A) in the oral composition of the present invention ((B)/(A)) ) Is not particularly limited, but from the viewpoint of significantly exhibiting the effect of the present invention, preferably 0.1 to 500 parts by mass, more preferably 0.5 to 200 parts by mass, further preferably 1 to 100 parts by mass, It is particularly preferably 5 to 50 parts by mass.

[(C) Water]
The oral composition of the present invention contains water. From the viewpoint of improving the feeling of use, the content of water is preferably 30% by mass or more, more preferably 40% by mass or more, and further preferably 50% by mass or more, based on the total amount of the oral composition. Is 80% by weight or less, more preferably 75% by weight or less, still more preferably 70% by weight or less.

[Medicinal properties]
The oral composition of the present invention, as long as the effect of the present invention is not impaired, as a medicinal component, for example, a bactericide (cationic bactericide (cetylpyridinium chloride, benzethonium chloride, chlorhexidine gluconate, chlorhexidine hydrochloride, etc.), Amphoteric fungicides (dodecylaminoethylglycine, etc.), nonionic fungicides (isopropylmethylphenol, hinokitiol, triclosan, thymol, 1,8-cineole, etc.), anionic fungicides (lauroylsarcosine sodium (LSS), etc.), Tissue repair agent (allantoin; allantoin β-glycyrrhetinic acid, allantoin dihydroxyaluminum (aldioxa), allantoin chlorhydroxyaluminum (alcloxa), allantoin polygalacturonic acid, allantoin ascorbic acid, allantoin acetyl-DL-methionine, allantoin DL-pantothenyl alcohol, Allantoin salts such as DL-pyrrolidone carboxylic acid sodium allantoin; panthenol etc.), anti-inflammatory agents (allantoin or its salts, tranexamic acid, glycyrrhizinic acid or its salts (dipotassium glycyrrhizinate, monoammonium glycyrrhizinate, etc.), β -Glycyrrhetinic acid or a derivative thereof (stearyl glycyrrhetinate, etc.), methyl salicylate, 1-menthol, tranexamic acid, ε-aminocaproic acid, oat extract, etc., bleeding inhibitor (carbazochrome, tranexamic acid, ε-aminocaproic acid, etc.), perception Hypersensitivity inhibitors (potassium nitrate, strontium chloride, aluminum lactate, etc.), blood circulation promoters (vitamin Es (α-tocopherol, β-tocopherol, γ-tocopherol, δ-tocopherol; tocopherol acetate such as dl-α-tocopherol acetate, nicotine) Acid tocopherol, tocopherol succinate, etc.), astringent (sodium chloride, etc.), remineralizing agent (sodium fluoride, sodium monofluorophosphate (MFP), tin fluoride, etc.), enzyme (lactoferrin, lactoperoxidase) , Dextranase, lysozyme, protease, amylase, mutanase, etc.), sodium copper chlorophyllin, magnesium L-ascorbyl phosphate, zinc chloride, sodium polyphosphate, sodium pyrophosphate and the like can be used in combination. These medicinal components may be used alone or in combination of two or more.

In the oral composition of the present invention, as long as the effect of the present invention is not impaired, asunaro extract, psyllium extract, Japanese laurel extract, sardine extract, chamomile extract, latania extract, myrrh extract, manuka honey extract, polyphenols, catechins , Medicinal ingredients derived from plants such as flavones and proanthocyanins can be used alone or in combination of two or more kinds.

The oral composition of the present invention, as long as the effects of the present invention are not impaired, as other medicinal components, zinc citrate, sanguinarine, delmopinol, nisin, chitosan, chlorophyll, etc., alone or in combination of two or more. It can be used in combination.

The oral composition of the present invention has at least one selected from the group consisting of a bactericidal agent, a tissue repairing agent, an anti-inflammatory agent, and a blood circulation promoting agent, as the medicinal component, from the viewpoint of more remarkably exhibiting the effect of the present invention. It is preferable to contain a cationic bactericide, allantoin, glycyrrhizinic acid or a salt thereof, β-glycyrrhetinic acid or a derivative thereof, and at least one selected from the group consisting of vitamin Es, and cetyl chloride. It is more preferable to contain at least one selected from the group consisting of pyridinium, allantoin, dipotassium glycyrrhizinate, β-glycyrrhetinic acid, and tocopherol acetate.

The medicinal component used in the composition for oral cavity of the present invention does not suppress the effect of the present invention whether it is water-soluble or water-insoluble, and the effect of the present invention has an action of enhancing adhesion to gums. Can be expected. Of these, water-soluble medicinal components are more preferable.

[Surfactant]
The oral composition of the present invention may further contain a surfactant. By containing the surfactant, the effect of the present invention is more remarkably exhibited.

As the surfactant, a nonionic surfactant, an amphoteric surfactant, an anionic surfactant, a cationic surfactant and the like can be used. Among them, it is preferable that at least one selected from the group consisting of nonionic surfactants and amphoteric surfactants is contained from the viewpoint of remarkably exerting the effect of the present invention.

Examples of nonionic surfactants include sorbitan monoisostearate, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, penta-2-ethylhexyl diglycerol sorbitan, tetra-2-ethylhexyl diglycerol. Sorbitan fatty acid esters such as sorbitan; polyoxyethylene (20) sorbitan monolaurate (polysorbate 20), polyoxyethylene (20) sorbitan monostearate (polysorbate 60), polyoxyethylene (20) sorbitan monooleate (polysorbate) 80), polyoxyethylene sorbitan fatty acid esters such as polyoxyethylene (20) sorbitan isostearate; polyethylene glycol fatty acid esters such as polyethylene glycol monooleate and polyethylene glycol monolaurate; propylene glycol fatty acid such as propylene glycol monostearate Esters; polyoxyethylene hydrogenated castor oil 40 (HCO-40), polyoxyethylene hydrogenated castor oil 50 (HCO-50), polyoxyethylene hydrogenated castor oil 60 (HCO-60), polyoxyethylene hydrogenated castor oil 80, etc. Hydrogenated castor oil derivative; fatty acid alkanolamide such as lauric acid diethanolamide; glycerin alkyl ether; alkyl glucoside such as lauryl glucoside and decyl glucoside; polyoxyalkylene alkyl such as polyoxyethylene (20) oleyl ether and polyoxyethylene cetyl ether Ether; polyglycerin fatty acid ester, polyoxyethylene glycerin fatty acid ester, polyoxyalkylene fatty acid ester, glycerin fatty acid ester such as glyceryl monostearate, sucrose fatty acid ester, sugar fatty acid ester such as maltose fatty acid ester; maltitol fatty acid ester, etc. Sugar alcohol fatty acid ester; polyoxyethylene lauryl alcohol ether and the like.

Examples of the amphoteric surfactant include imidazolinium betaines such as 2-alkyl-N-carboxymethyl-N-hydroxyethyl-N-imidazolinium betaine; alkylsulfobetaines such as laurylsulfobetaine and laurylhydroxysulfobetaine; Examples thereof include betaine acetate such as lauryl dimethylamino acetic acid betaine; palm oil fatty acid amide alkyl betaine such as coconut oil fatty acid amide propyl betaine; and long chain alkyl imidazoline betaine salt such as N-alkyl-1-hydroxyethyl imidazoline betaine sodium.

Examples of the anionic surfactant include alkyl sulfates (sodium lauryl sulfate, etc.), fatty acid monocarboxylates (laurate, palmitate, etc.), polyoxyethylene alkyl ether carboxylates, N-acyl sarcosine. Salt, N-acyl amino acid salt (N-acyl glutamate, etc.), dialkyl sulfosuccinate, alkane sulfonate (alkyl sulfonate), α-olefin sulfonate, linear alkylbenzene sulfonate, alkyl (branched chain) ) Benzene sulfonate, N-methyl-N-acyl taurate, polyoxyethylene alkyl ether sulfate, alkyl phosphate, polyoxyethylene alkyl ether phosphate, polyoxyethylene alkyl phenyl ether phosphate and the like. Be done.

Examples of the cationic surfactant include monoalkylamine salts, dialkylamine salts, trialkylamine salts, alkyltrimethylammonium salts, dialkyldimethylammonium salts, alkylbenzalkonium chlorides and the like.

Other surfactants include, for example, silicone surfactants such as polyoxyethylene/methylpolysiloxane copolymer, lauryl PEG-9 polydimethylsiloxyethyl dimethicone, and PEG-9 polydimethylsiloxyethyl dimethicone.

The surfactant is preferably a nonionic surfactant or an anionic surfactant, more preferably a nonionic surfactant, or a sorbitan fatty acid ester, or a polysiloxane, from the viewpoint of more significantly exhibiting the effect of the present invention. Oxyethylene sorbitan fatty acid esters are more preferred.
The total content of the surfactant is not particularly limited, and is appropriately set depending on the type of surfactant, the type and content of other compounding ingredients, the formulation form, the method of use, etc. From the viewpoint of more remarkably and sufficiently exerting the detergency, it is preferably 0.1 to 20% by mass, more preferably 0.5 to 10% by mass, and still more preferably the total amount of the oral composition. It is 1 to 7.5 mass %, particularly preferably 2 to 5 mass %.
When the surfactant is a nonionic surfactant, the total content of the nonionic surfactant is preferably 0.1 to 20% by mass, more preferably 0.5, with respect to the total amount of the oral composition. -10 mass%, more preferably 1-7.5 mass%, particularly preferably 2-5 mass%.

[hydrocarbon]
The oral composition of the present invention may further contain a hydrocarbon. By containing a hydrocarbon, the effect of the present invention is more remarkably exhibited.

As the hydrocarbon, a paraffinic hydrocarbon or an olefinic hydrocarbon is used, and examples thereof include liquid paraffin, petrolatum, squalane, squalene, ceresin, light liquid paraffin, paraffin wax, beeswax, carnauba wax, pristane, and microcrystalline wax. Can be mentioned. From the viewpoint of further enhancing the effect of the present invention, liquid paraffin or petrolatum is more preferable, and liquid paraffin is further preferable.

The total content of hydrocarbons is not particularly limited, and is appropriately set depending on the type of hydrocarbon, the type and content of other compounding components, the form of the formulation, the method of use, etc. From the viewpoint of playing, and from the viewpoint of further enhancing the feeling of use, it is preferably 0.5 to 30% by mass, more preferably 1 to 25% by mass, still more preferably 3 to 20% by mass, particularly preferably 3 to 20% by mass, relative to the total amount of the oral composition. Preferably it is 5.1 to 15 mass %.

[Other additives]
The oral composition of the present invention is a range that does not impair the effects of the present invention, and can be used as a drug, a quasi drug, a cosmetic, a food, a known higher alcohol, a solubilizer, a wetting agent, a preservative, Additives such as chelating agents, pH adjusters, sweeteners, flavors, and colorants can be added. These additives may be used alone or in combination of two or more.

Higher alcohols can be used in the oral composition of the present invention. The higher alcohol refers to an alcohol having 6 or more carbon atoms, and may have either a linear or branched structure. As the higher alcohol, but are not limited _to, C 8 _{-C 24} fatty alcohols are preferred. Such alcohols include cetanol (cetyl alcohol), stearyl alcohol, cetostearyl alcohol, lauryl alcohol, myristyl alcohol, oleyl alcohol, capryl alcohol, linoleyl alcohol, or behenyl alcohol. From the viewpoint of further enhancing the effect of the oral composition of the present invention, preferably one or more selected from cetanol, stearyl alcohol, and cetostearyl alcohol, more preferably one or more selected from cetanol or stearyl alcohol, and further preferably Cetanol is used.

Examples of the wetting agent include sugar alcohols such as xylitol, erythritol, maltitol, sorbitol, lactitol, trehalose, and mannitol; polyhydric alcohols such as ethylene glycol, propylene glycol, butylene glycol, polyethylene glycol, polypropylene glycol, and glycerin. ..

Preferable examples of the solubilizing agent include lower alcohols such as ethanol and propanol.

Examples of the preservative include parabens (methylparaben, ethylparaben, propylparaben, butylparaben, etc.), benzoic acid, sodium benzoate, dehydroacetic acid, sodium dehydroacetate, isobutyl paraoxybenzoate, isopropyl paraoxybenzoate, and paraoxybenzoic acid. Examples thereof include butyl, ethyl paraoxybenzoate, propyl paraoxybenzoate, benzyl paraoxybenzoate, methyl paraoxybenzoate, phenoxyethanol, alkyldiaminoethylglycine hydrochloride, benzalkonium chloride, and benzethonium chloride.

Examples of the chelating agent include EDTA.disodium salt and EDTA.calcium.disodium salt.

Examples of the pH adjuster include inorganic acids (hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, etc.), organic acids (lactic acid, citric acid, succinic acid, gluconic acid, maleic acid, adipic acid, succinic acid, etc.), inorganic bases ( Potassium hydroxide, sodium hydroxide, etc., organic bases (triethanolamine, diisopropanolamine, triisopropanolamine, etc.), salts (sodium lactate, sodium succinate, sodium citrate, sodium hydrogen citrate, sodium acetate, phosphoric acid) Examples thereof include sodium, sodium dihydrogen phosphate, sodium carbonate, sodium sesquicarbonate (trisodium monohydrogen dicarbonate), and basic amino acids (lysine, arginine, etc.).

Examples of the sweetener include sugars or sugar alcohols (xylitol, palatinose, erythritol, maltitol, arabitol), stevioside, stevia extract, thaumatin, glycyrrhizin, sucralose, acesulfame potassium, saccharin sodium, aspartame, neohesperidyl dihydrochalcone, perillartin and the like. Is mentioned.

[PH]
The pH of the oral composition of the present invention is appropriately set depending on the types of the components (A) and (B), the types and contents of other compounding components, the lumber form, the method of use, etc. It is not limited as long as it is within the allowable range, but it is preferably pH 3.5 to 9, more preferably 4 to 8, and still more preferably 4.5 to 7 from the viewpoint of improving the feeling of use.

[Use]
The oral composition of the present invention can be brought into contact with and closely adhere to the tissues in the oral cavity such as periodontal tissue and remain, so that the pharmacological component and the like can be continuously acted on the tissues in the oral cavity. Therefore, it can be used to improve or prevent periodontal diseases such as gingivitis and alveolar pyorrhea, to improve or prevent tooth diseases such as caries and hyperesthesia, and to improve the condition of tissues in the oral cavity. It is preferably used for amelioration or prevention of diseases.

The composition for oral cavity of the present invention may be in a mode not containing an abrasive. In that case, an effect of reducing friction generated between the oral tissues can be expected. More specifically, by applying the composition according to the present embodiment to a toothbrush or the like, it is possible to reduce the friction generated between the gum and the toothbrush when brushing the gum, and therefore, the oral cavity such as gums. It is preferable for the above-mentioned applications because it allows brushing without damaging the tissue.

Periodontal disease is broadly divided into two types depending on the progress of the condition: gum inflammation (gingivitis) and alveolar pyorrhea (periodontitis). The oral composition of the present invention can be used for improving or preventing any of these.

In the present specification, “adhering to the tissue in the oral cavity” means that the tissue adheres to the tissue in the oral cavity and stays there. Therefore, “adhesion” or “adhesion” can be interpreted by replacing “adhesion” or “adhesion” or “adhesion” or “adhesion”.

As used herein, the term "prevention" refers to preventing or delaying the onset of a disease or symptom, or reducing the risk of developing a disease or symptom.

Further, in the present specification, “improvement” means improvement or alleviation of a disease, symptom or health condition, prevention or delay of deterioration of disease, symptom or health condition, or reversal, prevention or delay of progression of disease or symptom. ..

[Dosage form]
The property of the composition for oral cavity of the present invention is not particularly limited as long as it is a form known as a drug, a quasi drug, or a cosmetic, and may be liquid, fluid, or semisolid. In addition, the formulation form may be, for example, a paste, cream, liquid, emulsion, ointment, gel, suspension, emulsion, lotion or the like. Among them, pastes, creams, solutions, emulsions or ointments are more preferable, pastes or creams are even more preferable, and creams are particularly preferable. When the paste, cream, liquid, emulsion, ointment, etc. contain an oily base and an aqueous base, they may be of O/W type or W/O type. However, an O/W type emulsion is preferable from the viewpoint of more remarkably exerting the effect of the present invention.

The form of the composition for oral cavity of the present invention is not particularly limited as long as it is a form known as a drug, quasi drug, cosmetic, or food, for example, a dentifrice, a coating agent, a mouthwash, and a beauty applied to gums. It can be used as a liquid, a mouthwash, etc. Among them, dentifrices, coating agents, and gargles are preferable, and dentifrices are more preferable, from the viewpoint of evenly spreading to tissues in the oral cavity and continuously contacting and penetrating medicinal components and nutritional components into tissues.

[Production method]
The composition for oral cavity of the present invention can be produced by a known method. A sterilization step can be included if desired.

[Method of enhancing adhesion to gums]
The method of enhancing the adhesion to the gums of the present invention is the following method.
A method for enhancing the adhesion of an oral composition to the gums, which comprises the step of containing (A) a fatty acid dextrin, (B) a polymer compound and/or an abrasive, and (C) water.

Regarding the formulation form and use of the oral composition, such as the types and contents of the components (A), (B) and (C), the types and contents of other components in the method, refer to [oral cavity Composition for use].

Next, the present invention will be specifically described with reference to Examples and Test Examples, but the present invention is not limited to the following Examples and Test Examples.

[Test Example 1. Adhesion test]
Dentifrice having the composition shown in Table 1 below was prepared by a conventional method, and the adhesive strength was evaluated using these.
The dentifrices shown in Table 1 (Comparative Examples 1-1 and 1-2, Examples 1-1 and 1-2) were prepared.
Next, put 200 mL of purified water and a cross-shaped stirrer with a diameter of 3 cm into a 200 mL beaker, and place 0.2 g of the preparation in the center of a slide glass (long side 7.6 cm, width 2.6 cm) with a thickness of about 1.4 mm. The solution was applied, and the beaker was dipped in such a manner that the preparation application surface was faced downward. At this time, the coating unit is installed about 1.5 cm above the stirring bar.
The knob of a stirrer (KPI, MIGHTY STIRRR, HE16GX6) was adjusted to 5, and the time (adhesion time) (second) until all the applied preparations floated up from the slide glass was measured. The power source used was 100 V AC and a frequency of 60 Hz.
Next, the adhesion improvement rate (%) of each example with respect to the corresponding comparative example was calculated by the following formula. The comparative example corresponding to Example 1-1 is Comparative Example 1-1, and the comparative example corresponding to Example 1-2 is Comparative Example 1-2.
<Adhesion rate improvement rate (%)>
Adhesion improvement rate (%)
=(Adhesion time of Example-Adhesion time of corresponding Comparative Example)/Adhesion time of corresponding Comparative Example x 100
Based on the calculated value of the adhesive force improvement rate (%), the evaluation was made according to the following criteria.
Less than 0%: ×
1% or more and less than 10%: △
10% or more and less than 20%: 〇 20% or more: ◎

As shown in Table 1, as compared with Comparative Example 1-1 containing a carboxyvinyl polymer and purified water and Comparative Example 1-2 containing sodium alginate and purified water, Example 1-1 further containing dextrin palmitate. In Example 1-2, it was confirmed that the adhesion rate was remarkably improved.

Further, the adhesive force improvement rates of Examples 1-1 and 2 with respect to Comparative Examples 1-1 and 2 were obtained using the same method as described above except that the stirrer knob was set to 10. As a result, the adhesive force improvement rates of Example 1-1 and Example 1-2 were both 10% or more.

Since dextrin palmitate is a gelling agent for fat-soluble components, it is used in W/O-based compositions, but it is not usually used in O/W-based compositions. However, the compositions of Examples 1-1 and 1-2 have excellent properties in terms of extruding from a tube, breakage of the preparation at the time of use, feeling of use at the time of brushing teeth, etc., together with the improvement of the adhesion rate. Was.

[Test Example 2. Usability test (1)]
A dentifrice having the composition shown in Table 1 of Test Example 1 was prepared by a conventional method, and the feeling of use was evaluated using these.
The dentifrices shown in Table 1 (Comparative Example 1-1, Example 1-1) were prepared.
To the three panelists including the dentifrice developer, put 0.5g of each dentifrice on the toothbrush and have them brush their teeth. Feel the adhesiveness on the gums and the unpleasant acidity after 1 minute from the start of brushing. The degree was evaluated based on the following criteria.
The results are shown in Table 2.
<Evaluation criteria for adhesion to gums>
Feel a strong feeling of contact: 5
Feeling close contact: 4
Feel a little close to each other: 3
Almost no feeling of contact :2
I don't feel any contact :1
<Unpleasant sourness evaluation criteria>
Feeling unbearably sour: 5
Feel a strong and unpleasant acidity: 4
Feels unpleasantly sour to the extent that it can be clearly recognized: 3
Slightly unpleasant sourness: 2
Almost no unpleasant sourness: 1

In Example 1-1, it was possible to clearly feel an improvement in the adhesive force to the gums as compared with Comparative Example 1-1. Further, in Comparative Example 1-1, an unpleasant sourness was felt, but in Example 2 containing the dextrin palmitate as the (A) component in addition to the (B) component, the unpleasant sourness was not felt, and it was comfortable. Could be used for.

[Test Example 3. Usability test (2)]
Dentifrice having the composition shown in Table 3 below was prepared by a conventional method, and the feeling of use was evaluated using these.
The dentifrices shown in Table 3 (Comparative Example 2, Example 2) were prepared.
To the three panelists including the dentifrice developer, put 0.5g of each dentifrice on the toothbrush and have them brush their teeth. Feel the adhesiveness on the gums and the unpleasant acidity after 1 minute from the start of brushing. Regarding the degree, it was evaluated which dentifrice was more felt when used.
The results are shown in Table 4.

As in Example 2, even when the concentration of each component such as carboxyvinyl polymer was changed in place of the formulation example of Table 1, the feeling of adhesion to the gums was improved as compared with the case where dextrin palmitate was not contained. It was confirmed that the effect and the effect of suppressing unpleasant sourness were obtained. Further, in comparison with Comparative Example 2, in Example 2, there was a tendency that the irritation felt during use was reduced.

Therefore, from Test Examples 2 and 3, when the high molecular compound was contained as the component (B), by combining the dextrin palmitate as the component (A), the feeling of adhesion to the gums was improved and unpleasant sourness It was revealed that the effect of suppressing

[Example of formulation]
Hereinafter, some formulation examples using the oral composition according to the present invention will be described. The following formulation examples can be prepared by a conventional method in the formulation described below. The unit of the content of each component is all w/w%.

(Formulation Example 1) Dentifrice Allantoin 0.1
Tocopherol acetate 0.04
Cetylpyridinium chloride hydrate 0.02
Dipotassium glycyrrhizinate 0.2
Mint oil 0.3
Lily extract 0.1
Hydrolyzed conchiolin solution 0.1
Liquid paraffin 10
White vaseline 1
Dextrin palmitate 0.5
Sorbitan monostearate 1.5
Carboxyvinyl polymer 1.1
Pullulan 0.1
Polysorbate 60 1.5
Lauryl sulfate Na 1
Concentrated glycerin 5
Paraben 0.1
Fragrance 0.2
L-Arginine Suitable amount
Purified water Total remaining amount 100

(Formulation Example 2) Dentifrice Tocopherol Acetate 0.04
Isopropyl methylphenol 0.05
Hinokitiol 0.1
Potassium nitrate 5
Sodium chloride 5
Peppermint oil 1
Lily extract 0.05
Liquid paraffin 6
Dextrin palmitate 0.5
Glycerin monostearate 1.5
Carboxy vinyl polymer 0.5
Sodium alginate 0.5
Polyoxyethylene cetyl ether 1.5
Lauroyl methyl taurine Na 1
Propylene glycol 5
Phenoxyethanol 0.3
Perfume 0.1
L-Arginine Suitable amount
Purified water Total remaining amount 100

(Formulation Example 3) Dentifrice benzalkonium chloride 0.01
Sodium monofluorophosphate 0.07
Lauroyl sarcosine Na 0.2
Polyethylene glycol a 5
Menthol 0.3
Hydrolyzed conchiolin liquid 1
Liquid paraffin 5
White petrolatum 0.1
Dextrin palmitate 0.5
Sorbitan monostearate 1.5
Calcium hydrogen phosphate 10
Polyoxyethylene hydrogenated castor oil 1.5
2-alkyl-N-carboxymethyl-
N-hydroxyethyl imidazolinium betaine 1
1,3-butylene glycol 5
Phenoxyethanol 0.5
Fragrance 0.05
L-Arginine Suitable amount
Purified water Total remaining amount 100

Claims (12)

An oral composition containing (A) a fatty acid dextrin, (B) a polymer compound and/or an abrasive, and (C) water. The oral composition according to claim 1, wherein the polymer compound (B) and/or the abrasive is a linear polymer compound. The (B) polymer compound and/or abrasive is at least one selected from the group consisting of carboxyvinyl polymer, alginic acid or a salt thereof, pullulan, and a cellulosic polymer. Composition for oral cavity. The composition for oral cavity according to any one of claims 1 to 3, wherein the total content of the component (B) is 0.01 to 500 parts by mass with respect to the total content of the component (A) of 1 part by mass. (C) The composition for oral cavity according to any one of claims 1 to 4, which contains 30% by mass or more of water. The oral composition according to any one of claims 1 to 5, wherein the fatty acid dextrin (A) is dextrin palmitate. The oral composition according to claim 1, further comprising at least one selected from the group consisting of a bactericide, a tissue repair agent, an anti-inflammatory agent, and a blood circulation promoter. Furthermore, the composition for oral cavity according to any one of claims 1 to 7, which contains a higher alcohol. Furthermore, the composition for oral cavity as described in any one of Claims 1-8 containing a surfactant. Furthermore, the composition for oral cavity of any one of Claims 1-9 containing a hydrocarbon. The oral composition according to any one of claims 1 to 10, which is a dentifrice, a coating agent, or a mouthwash. A method for enhancing the adhesion of an oral composition to the gums, which comprises the step of containing (A) a fatty acid dextrin, (B) a polymer compound and/or an abrasive, and (C) water.